Skip to main content

Students in Quebec are the first in Canada to be vaccinated in a program that uses two different vaccines to protect against the human papillomavirus, a change that has divided experts.

Under the new program, which started this fall, students receive one shot of Gardasil 9, which protects against nine strains of HPV, including 16 and 18, the two that cause the majority of cervical, anal and other HPV-related cancers. Early next year, students will receive a shot of Cervarix, which protects against HPV 16 and 18 only.

The new schedule is expected to save the Quebec government $3-million a year.

Story continues below advertisement

Several experts and organizations call the change a risky experiment that puts savings over health. None of the experts dispute the safety of Cervarix. The concern is that students who do not get two doses of Gardasil 9 will not build sufficient immunity to seven of the nine strains. Cervarix, produced by GlaxoSmithKline (GSK), costs about $110 per dose, while Gardasil 9, made by Merck, costs about $190.

“[The change] took a lot of us by surprise,” said Nancy Durand, a gynecologist at Toronto’s Sunnybrook Health Sciences Centre. “It’s a living experiment."

But members of Quebec’s immunization committee say clinical evidence shows the amended vaccine program will protect young people. Committee member Vladimir Gilca says much of the backlash originates from Merck, which stands to lose if provinces reduce use of its vaccine. School-based HPV vaccination programs in every other province use two doses of Gardasil 9.

“It’s nothing new to change a vaccination program. Most of these changes pass without a lot of attention,” said Dr. Gilca, a scientific adviser for the National Public Health Institute of Quebec.

Some of the opposition is because Cervarix has been approved for use only in girls and women in Canada. That does not mean it is unsafe for boys, but it is unusual for policy-makers to use vaccines in this off-label way, said Marc Steben, who works in the unit for sexually transmitted infections of the National Public Health Institute of Quebec.

Some experts fear one dose of Gardasil 9 could leave students vulnerable to genital warts and other less common forms of cancer not covered by Cervarix.

“This is based on pretty skimpy evidence, particularly in terms of long-term outcomes,” said Zeev Rosberger, a psychologist who studies HPV prevention and is on the board of advocacy group HPV Awareness.

Story continues below advertisement

Quebec’s health ministry declined an interview request.

But the immunization committee says there are good reasons for the change. The group’s recommendations, published earlier this year, say two studies conducted in Quebec show students vaccinated with Gardasil 9 and Cervarix have high levels of immunity to the main cancer-causing strains HPV 16 and 18. The shot of Cervarix also boosted immune response to some of the other HPV strains included in Gardasil 9. However, the committee notes that immunity levels to HPV 6 and 11, which cause genital warts, are lower in students vaccinated in the mixed program. They may still build sufficient immunity against HPV 6 and 11, but the committee says the province should monitor the issue.

Chantal Sauvageau, a committee member and medical consultant at the province’s public health institute, said Cervarix is approved for boys in Europe. It is not approved here because the company has not applied to Health Canada, she said.

Dr. Gilca and Dr. Sauvageau say Merck is trying to influence public perception of the new vaccination program.

In September, Merck sent a letter to doctors in Quebec stating the company “disagrees with the change in the program" because Cervarix is not approved for boys. The same day, HPV Awareness issued a press release urging the public to ask Quebec’s health minister to reverse the change. HPV Awareness said it received a $30,000 grant from Merck this year to conduct an HPV education campaign. Amélie McFadyen, the group’s executive director, said the company has no input over content.

A week later, the Federation of Medical Women of Canada issued a statement criticizing Quebec’s HPV vaccination changes, saying the “new, untested” plan is “worrisome.” In an e-mail, federation president Kathee Andrews said Merck provided the group with a grant to fund its HPV prevention initiatives.

Story continues below advertisement

Merck ran a national ad campaign last week highlighting its role in protecting Canadians against HPV-related cancers and diseases. In a statement, Merck Canada said Quebec’s new program “could put children at risk by inadequately protecting them." The company said it abides by ethics rules when it collaborates with health-care professionals and organizations.

Dr. Steben, who is on the board of directors of HPV Awareness, was lead author of a study on Gardasil published in October and funded by Merck. In the study, he disclosed receiving grants and personal fees from Merck. In an interview, Dr. Steben said the relationship does not affect his views and the company does not tell him what to say.

Dr. Durand said she has been on advisory boards for GSK and Merck and speaks on behalf of Merck at educational meetings. She said the relationship does not pose a conflict.

Dr. Gilca said he has not received funding from GSK or Merck as long as the HPV vaccines have been on the market, and said he has no financial relationship to any vaccine manufacturer. Dr. Sauvageau received funding for presentations from GSK and Merck in 2010.

Report an error Editorial code of conduct
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter